Drug Profile


Alternative Names: CA-18C3; CV-18C3; Human IGG1 monoclonal antibody specific for human interleukin-1 alpha; Hutruo; MAB-p1; RA-18C3; T2-18C3; Xilonix

Latest Information Update: 06 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator XBiotech
  • Developer Cedars-Sinai Medical Center; Hellenic Institute for the Study of Sepsis; Ipsen; XBiotech
  • Class Anti-inflammatories; Antihyperglycaemics; Antineoplastics; Antipsoriatics; Antirheumatics; Monoclonal antibodies; Vascular disorder therapies
  • Mechanism of Action Angiogenesis inhibitors; Immunomodulators; Interleukin 1 alpha inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preregistration Colorectal cancer
  • Phase III Cachexia
  • Phase II Acne vulgaris; Hidradenitis suppurativa; Non-small cell lung cancer; Plaque psoriasis; Pyoderma; Type 2 diabetes mellitus; Vascular restenosis
  • No development reported Haematological malignancies

Most Recent Events

  • 04 Dec 2017 Efficacy data from a phase II trial in Hidradenitis suppurativa released by XBiotech
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Haematological-malignancies in USA (IV)
  • 18 Oct 2017 Phase-I clinical trials in Cachexia (Adjunctive treatment) in patients with pancreatic cancer in USA (IV) (NCT03207724)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top